Nektar Therapeutics (NKTR)
0.49
-0.06 (-11.22%)
At close: Apr 07, 2025, 3:59 PM
0.50
1.51%
Pre-market: Apr 08, 2025, 04:31 AM EDT
-11.22% (1D)
| Bid | 0.47 |
| Market Cap | 91.25M |
| Revenue (ttm) | 98.43M |
| Net Income (ttm) | -118.96M |
| EPS (ttm) | -0.58 |
| PE Ratio (ttm) | -0.85 |
| Forward PE | -0.98 |
| Analyst | Buy |
| Ask | 0.6 |
| Volume | 4,203,847 |
| Avg. Volume (20D) | 2,160,958 |
| Open | 0.53 |
| Previous Close | 0.55 |
| Day's Range | 0.47 - 0.55 |
| 52-Week Range | 0.47 - 1.93 |
| Beta | 0.69 |
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and a...
Industry Biotechnology
Sector Healthcare
IPO Date May 3, 1994
Employees 61
Stock Exchange NASDAQ
Ticker Symbol NKTR
Website https://www.nektar.com
Analyst Forecast
According to 5 analyst ratings, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 1123.74% from the latest price.
Stock ForecastsNext Earnings Release
Nektar Therapeutics is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+9.98%
Nekar Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
1 month ago
+3.55%
Nektar Therapeutics shares are trading higher after the company received Fast Track designation for Rezpegaldesleukin for the treatment of moderate-to-severe atopic dermatitis.
